Navigation Links
SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Spain
Date:6/24/2009

SAN DIEGO, June 24 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that it has established a distribution partnership in the Spanish market through SIM, a Madrid based firm specializing in the marketing and distribution of innovative medical devices.

Michel Vaudry, SpectraScience's VP of Sales and Marketing, said, "We are pleased to add another distribution partner in Europe. SIM is a respected and well established medical distribution company and adding the WavSTAT Optical Biopsy System to their portfolio is a strong validation of the need for our technology. SIM was established in 2000 and distributes other leading gastroenterological diagnostic products from market leaders including PENTAX and ERBE."

SIM's Consejero Delegado, Jose Manuel Ruiz, stated that, "We are pleased to be SpectraScience's distribution partner and believe there is significant market potential for this innovative gastrointestinal cancer diagnostic system. Our strategy is to be the leader in gastro-diagnostics and the WavSTAT Optical Biopsy System is an ideal fit with our PENTAX endoscopes. We see important benefits to our physicians, enabling them to quickly distinguish between normal and precancerous tissue in the GI tract and allowing for physical biopsy at exactly the same site and time that an optical biopsy is performed. More importantly, the WavSTAT objectively identifies the borders of tissue during surgery to determine if all cancerous tissue has been removed. This can prevent additional costly treatment."

Vaudry added, "Mr. Ruiz is a respected thought leader in the healthcare market and his company's support of the WavSTAT System will be instrumental in our acceptance at the major gastroenterology centers in Spain. SIM is a perfect partner for SpectraScience as they also represent PENTAX. PENTAX is one of the leading manufacturers of endoscopes which are used in conjunction with our product."

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provides the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. In addition, the Company's LUMA(R) Cervical Imaging technology has received FDA approval as an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available today.

    Contact:

    SpectraScience, Inc.                         Hayden Communications
    Jim Hitchin, Chief Executive Officer         Investor Relations
    (858) 847-0200 x 201                         Todd Pitcher
   http://www.spectrascience.com                (858)-518-1387


'/>"/>
SOURCE SpectraScience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. SpectraScience Receives FDA Clearance for Manufacturing Facility
2. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Greece & Cyprus
3. SpectraScience, Inc. Enters Into $6.0 Million Common Stock Purchase Agreement
4. SpectraScience Announces Business Update
5. SpectraScience Awarded U.S. Patent 7,469,160 for Its Unique Methods and Apparatus for Evaluating Image Focus
6. SpectraScience Awarded U.S. Patent 7,459,696 for its Unique Methods of Calibrating Spectral Data
7. SpectraScience Awarded European Patent for Its Optical Biopsy System for Tissue Diagnosis
8. SpectraScience Announces Updates
9. SpectraScience Delivers Cancer Diagnosis System to Mayo Clinic and UCSD/VA for Detecting Esophageal Dysplasia in Patients
10. SpectraScience Awarded Patent for Correcting Image Misalignment
11. SpectraScience Adds Industry Veteran to Executive Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
(Date:6/23/2016)... June 23, 2016 The vast majority of ... dialysis facility.  Treatments are usually 3 times a week, ... visit, including travel time, equipment preparation and wait time. ... especially grueling for patients who are elderly and frail.  ... nursing and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: